Royal Bank Of Canada Adverum Biotechnologies, Inc. Transaction History

Royal Bank Of Canada

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$0.75 - $1.26 $14 - $23	19 Added 44.19%	62 $0
Q3 2023 Nov 14, 2023	SELL	$1.5 - $2.33 $3,538 - $5,496	-2,359 Reduced 98.21%	43 $0
Q2 2023 Aug 14, 2023	BUY	$0.68 - $1.59 $469 - $1,097	690 Added 40.3%	2,402 $3,000
Q1 2023 May 15, 2023	BUY	$0.62 - $0.85 $187 - $257	303 Added 21.5%	1,712 $1,000
Q4 2022 Feb 14, 2023	SELL	$0.54 - $10.3 $595 - $11,350	-1,102 Reduced 43.89%	1,409 $0
Q3 2022 Nov 14, 2022	BUY	$0.96 - $9.68 $2,129 - $21,470	2,218 Added 757.0%	2,511 $2,000
Q2 2022 Aug 15, 2022	SELL	$0.81 - $1.34 $4,086 - $6,760	-5,045 Reduced 94.51%	293 $0
Q1 2022 May 16, 2022	SELL	$1.23 - $1.95 $12,630 - $20,024	-10,269 Reduced 65.8%	5,338 $7,000
Q4 2021 Feb 14, 2022	BUY	$1.74 - $2.4 $12,757 - $17,596	7,332 Added 88.6%	15,607 $27,000
Q3 2021 Nov 15, 2021	BUY	$2.08 - $3.6 $2,242 - $3,880	1,078 Added 14.98%	8,275 $18,000
Q2 2021 Aug 16, 2021	BUY	$3.36 - $10.56 $24,181 - $76,000	7,197 New	7,197 $25,000

524K

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $449M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.